Annual report
7446.TEDINET S100UZ2P
Period2023-10-01 → 2024-09-30
Filed2024-12-20
StandardJapan GAAP
ConsolidatedYes
Data checks24 of 24 passed
Key figures · 148
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥32.2bn | 2023-10-01 → 2024-09-30 | Cons. | Net sales |
| Revenue | ¥35.1bn | 2022-10-01 → 2023-09-30 | Cons. | Net sales |
| Revenue | ¥37.3bn | 2021-10-01 → 2022-09-30d | Cons. | Net sales (5-year summary) |
| Revenue | ¥36.2bn | 2020-10-01 → 2021-09-30d | Cons. | Net sales (5-year summary) |
| Revenue | ¥31.0bn | 2019-10-01 → 2020-09-30d | Cons. | Net sales (5-year summary) |
| Operating income | ¥353m | 2023-10-01 → 2024-09-30 | Cons. | Operating income |
| Operating income | ¥751m | 2022-10-01 → 2023-09-30 | Cons. | Operating income |
| Ordinary income | ¥408m | 2023-10-01 → 2024-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥808m | 2022-10-01 → 2023-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥1.0bn | 2021-10-01 → 2022-09-30d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥759m | 2020-10-01 → 2021-09-30d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥410m | 2019-10-01 → 2020-09-30d | Cons. | Ordinary income loss (5-year summary) |
| Profit before tax | ¥380m | 2023-10-01 → 2024-09-30 | Cons. | Income before income taxes |
| Profit before tax | ¥805m | 2022-10-01 → 2023-09-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥237m | 2023-10-01 → 2024-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥556m | 2022-10-01 → 2023-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥658m | 2021-10-01 → 2022-09-30d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥517m | 2020-10-01 → 2021-09-30d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥378m | 2019-10-01 → 2020-09-30d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income | ¥240m | 2023-10-01 → 2024-09-30 | Cons. | Profit loss |
| Net income | ¥567m | 2022-10-01 → 2023-09-30 | Cons. | Profit loss |
| Total assets | ¥17.2bn | at 2024-09-30 | Cons. | Assets |
| Total assets | ¥18.9bn | at 2023-09-30 | Cons. | Assets |
| Total assets | ¥17.5bn | at 2022-09-30d | Cons. | Total assets (5-year summary) |
| Total assets | ¥16.1bn | at 2021-09-30d | Cons. | Total assets (5-year summary) |
| Total assets | ¥14.6bn | at 2020-09-30d | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥9.7bn | at 2024-09-30 | Cons. | Liabilities |
| Total liabilities | ¥11.7bn | at 2023-09-30 | Cons. | Liabilities |
| Net assets / equity | ¥7.5bn | at 2024-09-30 | Cons. | Net assets |
| Net assets / equity | ¥7.3bn | at 2023-09-30 | Cons. | Net assets |
| Net assets / equity | ¥6.7bn | at 2022-09-30d | Cons. | Net assets |
| Net assets / equity | ¥6.3bn | at 2021-09-30d | Cons. | Net assets (5-year summary) |
| Net assets / equity | ¥5.7bn | at 2020-09-30d | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥764m | at 2024-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥2.2bn | at 2023-09-30 | Cons. | Cash and deposits |
| Cash & equivalents | ¥745m | at 2024-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥2.1bn | at 2023-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥1.3bn | at 2022-09-30d | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥660m | at 2021-09-30d | Cons. | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥730m | at 2020-09-30d | Cons. | Cash and cash equivalents (5-year summary) |
| Operating cash flow | −¥1.0bn | 2023-10-01 → 2024-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥1.3bn | 2022-10-01 → 2023-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥886m | 2021-10-01 → 2022-09-30d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥322m | 2020-10-01 → 2021-09-30d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥441m | 2019-10-01 → 2020-09-30d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | −¥108m | 2023-10-01 → 2024-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥335m | 2022-10-01 → 2023-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥92m | 2021-10-01 → 2022-09-30d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥172m | 2020-10-01 → 2021-09-30d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | ¥205m | 2019-10-01 → 2020-09-30d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | −¥210m | 2023-10-01 → 2024-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥96m | 2022-10-01 → 2023-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥186m | 2021-10-01 → 2022-09-30d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥221m | 2020-10-01 → 2021-09-30d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥511m | 2019-10-01 → 2020-09-30d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥263.54 | 2023-10-01 → 2024-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥617.29 | 2022-10-01 → 2023-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥728.76 | 2021-10-01 → 2022-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥564.91 | 2020-10-01 → 2021-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥404.57 | 2019-10-01 → 2020-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| Net assets per share | ¥8,233.87 | at 2024-09-30 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥7,971.19 | at 2023-09-30 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥7,330.63 | at 2022-09-30d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥6,829.86 | at 2021-09-30d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥6,023.38 | at 2020-09-30d | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 43.0% | at 2024-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 38.0% | at 2023-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 37.7% | at 2022-09-30d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 38.6% | at 2021-09-30d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 38.5% | at 2020-09-30d | Cons. | Equity to asset ratio (5-year summary) |
| ROE | 3.3% | 2023-10-01 → 2024-09-30 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 8.1% | 2022-10-01 → 2023-09-30 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 10.2% | 2021-10-01 → 2022-09-30d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 8.7% | 2020-10-01 → 2021-09-30d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 6.9% | 2019-10-01 → 2020-09-30d | Cons. | Rate of return on equity (5-year summary) |
| Employees | 330 | at 2024-09-30 | Cons. | Number of employees |
| Employees | 321 | at 2023-09-30 | Cons. | Number of employees |
| Employees | 321 | at 2022-09-30d | Cons. | Number of employees |
| Employees | 316 | at 2021-09-30d | Cons. | Number of employees |
| Employees | 314 | at 2020-09-30d | Cons. | Number of employees |
| Revenue | ¥24.7bn | 2023-10-01 → 2024-09-30 | Standalone | Net sales |
| Revenue | ¥27.4bn | 2022-10-01 → 2023-09-30 | Standalone | Net sales |
| Revenue | ¥28.4bn | 2021-10-01 → 2022-09-30d | Standalone | Net sales (5-year summary) |
| Revenue | ¥27.8bn | 2020-10-01 → 2021-09-30d | Standalone | Net sales (5-year summary) |
| Revenue | ¥24.4bn | 2019-10-01 → 2020-09-30d | Standalone | Net sales (5-year summary) |
| Operating income | ¥345m | 2023-10-01 → 2024-09-30 | Standalone | Operating income |
| Operating income | ¥687m | 2022-10-01 → 2023-09-30 | Standalone | Operating income |
| Ordinary income | ¥393m | 2023-10-01 → 2024-09-30 | Standalone | Ordinary income |
| Ordinary income | ¥739m | 2022-10-01 → 2023-09-30 | Standalone | Ordinary income |
| Ordinary income | ¥846m | 2021-10-01 → 2022-09-30d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥633m | 2020-10-01 → 2021-09-30d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥380m | 2019-10-01 → 2020-09-30d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥368m | 2023-10-01 → 2024-09-30 | Standalone | Income before income taxes |
| Profit before tax | ¥719m | 2022-10-01 → 2023-09-30 | Standalone | Income before income taxes |
| Net income | ¥230m | 2023-10-01 → 2024-09-30 | Standalone | Profit loss |
| Net income | ¥495m | 2022-10-01 → 2023-09-30 | Standalone | Profit loss |
| Net income | ¥547m | 2021-10-01 → 2022-09-30d | Standalone | Net income loss (5-year summary) |
| Net income | ¥424m | 2020-10-01 → 2021-09-30d | Standalone | Net income loss (5-year summary) |
| Net income | ¥356m | 2019-10-01 → 2020-09-30d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥13.6bn | at 2024-09-30 | Standalone | Assets |
| Total assets | ¥15.2bn | at 2023-09-30 | Standalone | Assets |
| Total assets | ¥14.1bn | at 2022-09-30d | Standalone | Total assets (5-year summary) |
| Total assets | ¥13.0bn | at 2021-09-30d | Standalone | Total assets (5-year summary) |
| Total assets | ¥11.7bn | at 2020-09-30d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥6.6bn | at 2024-09-30 | Standalone | Liabilities |
| Total liabilities | ¥8.4bn | at 2023-09-30 | Standalone | Liabilities |
| Net assets / equity | ¥7.0bn | at 2024-09-30 | Standalone | Net assets |
| Net assets / equity | ¥6.8bn | at 2023-09-30 | Standalone | Net assets |
| Net assets / equity | ¥6.3bn | at 2022-09-30d | Standalone | Net assets |
| Net assets / equity | ¥6.0bn | at 2021-09-30d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥5.5bn | at 2020-09-30d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥663m | at 2024-09-30 | Standalone | Cash and deposits |
| Cash and deposits | ¥2.1bn | at 2023-09-30 | Standalone | Cash and deposits |
| EPS (basic) | ¥255.69 | 2023-10-01 → 2024-09-30 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥549.54 | 2022-10-01 → 2023-09-30 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥606.07 | 2021-10-01 → 2022-09-30d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥463.89 | 2020-10-01 → 2021-09-30d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥380.41 | 2019-10-01 → 2020-09-30d | Standalone | Basic earnings loss per share (5-year summary) |
| Dividend per share | ¥105 | 2023-10-01 → 2024-09-30 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥105 | 2022-10-01 → 2023-09-30 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥115 | 2021-10-01 → 2022-09-30d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥105 | 2020-10-01 → 2021-09-30d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥90 | 2019-10-01 → 2020-09-30d | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥7,802.34 | at 2024-09-30 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥7,552.81 | at 2023-09-30 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥6,987.67 | at 2022-09-30d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥6,615.32 | at 2021-09-30d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥5,917.64 | at 2020-09-30d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 51.5% | at 2024-09-30 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 44.8% | at 2023-09-30 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 44.7% | at 2022-09-30d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 46.4% | at 2021-09-30d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 47.4% | at 2020-09-30d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 3.3% | 2023-10-01 → 2024-09-30 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 7.6% | 2022-10-01 → 2023-09-30 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 8.9% | 2021-10-01 → 2022-09-30d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 7.3% | 2020-10-01 → 2021-09-30d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 6.6% | 2019-10-01 → 2020-09-30d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 960,000 | at 2024-09-30 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 960,000 | at 2023-09-30 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 960,000 | at 2022-09-30d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 960,000 | at 2021-09-30d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 960,000 | at 2020-09-30d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 254 | at 2024-09-30 | Standalone | Number of employees |
| Employees | 244 | at 2023-09-30 | Standalone | Number of employees |
| Employees | 236 | at 2022-09-30d | Standalone | Number of employees |
| Employees | 230 | at 2021-09-30d | Standalone | Number of employees |
| Employees | 228 | at 2020-09-30d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 22
| Segment | Item | Period | Value |
|---|---|---|---|
| Academia Life Science Sales Groupreportable segment | employees | at 2024-09-30 | 24 pure |
| Academia Life Science Sales Groupreportable segment | revenue | 2023-10-01 → 2024-09-30 | ¥1.9bn |
| Academia Life Science Sales Groupreportable segment | revenue external | 2023-10-01 → 2024-09-30 | ¥1.9bn |
| Industry Sales Groupreportable segment | employees | at 2024-09-30 | 59 pure |
| Industry Sales Groupreportable segment | revenue | 2023-10-01 → 2024-09-30 | ¥16.1bn |
| Industry Sales Groupreportable segment | revenue external | 2023-10-01 → 2024-09-30 | ¥16.1bn |
| Medical Sales Groupreportable segment | employees | at 2024-09-30 | 78 pure |
| Medical Sales Groupreportable segment | revenue | 2023-10-01 → 2024-09-30 | ¥14.1bn |
| Medical Sales Groupreportable segment | revenue external | 2023-10-01 → 2024-09-30 | ¥14.1bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2023-10-01 → 2024-09-30 | ¥32.2bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2023-10-01 → 2024-09-30 | ¥32.2bn |
| Academia Life Science Sales Groupreportable segment | revenue | 2022-10-01 → 2023-09-30 | ¥2.2bn |
| Academia Life Science Sales Groupreportable segment | revenue external | 2022-10-01 → 2023-09-30 | ¥2.2bn |
| Industry Sales Groupreportable segment | revenue | 2022-10-01 → 2023-09-30 | ¥17.5bn |
| Industry Sales Groupreportable segment | revenue external | 2022-10-01 → 2023-09-30 | ¥17.5bn |
| Medical Sales Groupreportable segment | revenue | 2022-10-01 → 2023-09-30 | ¥15.4bn |
| Medical Sales Groupreportable segment | revenue external | 2022-10-01 → 2023-09-30 | ¥15.4bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-10-01 → 2023-09-30 | ¥35.1bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-10-01 → 2023-09-30 | ¥35.1bn |
| Academia Life Science Sales Groupreportable segment | employees | at 2024-09-30 | 24 pure |
| Industry Sales Groupreportable segment | employees | at 2024-09-30 | 49 pure |
| Medical Sales Groupreportable segment | employees | at 2024-09-30 | 31 pure |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,602
| Item | Context | Value | Unit |
|---|---|---|---|
| Current liabilities | CurrentYearInstant | 8711479000 | JPY |
| Long term loans payable | Prior1YearInstant | 27410000 | JPY |
| Long term loans payable | CurrentYearInstant | 38730000 | JPY |
| Lease obligations ncl | Prior1YearInstant | 201836000 | JPY |
| Lease obligations ncl | CurrentYearInstant | 429619000 | JPY |
| Deferred tax liabilities | Prior1YearInstant | 282841000 | JPY |
| Deferred tax liabilities | CurrentYearInstant | 304843000 | JPY |
| Net defined benefit liability | Prior1YearInstant | 80365000 | JPY |
| Net defined benefit liability | CurrentYearInstant | 67090000 | JPY |
| Provision for directors retirement benefits | Prior1YearInstant | 142012000 | JPY |
| Provision for directors retirement benefits | CurrentYearInstant | 118798000 | JPY |
| Other ncl | Prior1YearInstant | 44232000 | JPY |
| Other ncl | CurrentYearInstant | 61343000 | JPY |
| Noncurrent liabilities | Prior1YearInstant | 778697000 | JPY |
| Noncurrent liabilities | CurrentYearInstant | 1020425000 | JPY |
| Liabilities | Prior1YearInstant | 11651650000 | JPY |
| Liabilities | CurrentYearInstant | 9731904000 | JPY |
| Capital stock | Prior1YearInstant | 820400000 | JPY |
| Capital stock | CurrentYearInstant | 820400000 | JPY |
| Capital surplus | Prior1YearInstant | 881100000 | JPY |
| Capital surplus | CurrentYearInstant | 881100000 | JPY |
| Retained earnings | Prior1YearInstant | 4946792000 | JPY |
| Retained earnings | CurrentYearInstant | 5089637000 | JPY |
| Treasury stock | Prior1YearInstant | -168907000 | JPY |
| Treasury stock | CurrentYearInstant | -169040000 | JPY |
| Shareholders equity | Prior1YearInstant | 6479385000 | JPY |
| Shareholders equity | CurrentYearInstant | 6622097000 | JPY |
| Valuation difference on available for sale securities | Prior1YearInstant | 697779000 | JPY |
| Valuation difference on available for sale securities | CurrentYearInstant | 786144000 | JPY |
| Remeasurements of defined benefit plans | Prior1YearInstant | 5057000 | JPY |
| Remeasurements of defined benefit plans | CurrentYearInstant | 10387000 | JPY |
| Valuation and translation adjustments | Prior1YearInstant | 702836000 | JPY |
| Valuation and translation adjustments | CurrentYearInstant | 796531000 | JPY |
| Non controlling interests | Prior1YearInstant | 86867000 | JPY |
| Non controlling interests | CurrentYearInstant | 88942000 | JPY |
| Net assets | Prior1YearInstant | 7269089000 | JPY |
| Net assets | CurrentYearInstant | 7507572000 | JPY |
| Liabilities and net assets | Prior1YearInstant | 18920740000 | JPY |
| Liabilities and net assets | CurrentYearInstant | 17239477000 | JPY |
| Net sales | Prior1YearDuration | 35094627000 | JPY |
| Net sales | CurrentYearDuration | 32155676000 | JPY |
| Cost of sales | Prior1YearDuration | 31750175000 | JPY |
| Cost of sales | CurrentYearDuration | 29016058000 | JPY |
| Gross profit | Prior1YearDuration | 3344452000 | JPY |
| Gross profit | CurrentYearDuration | 3139618000 | JPY |
| Selling general and administrative expenses | Prior1YearDuration | 2593455000 | JPY |
| Selling general and administrative expenses | CurrentYearDuration | 2786360000 | JPY |
| Operating income | Prior1YearDuration | 750996000 | JPY |
| Operating income | CurrentYearDuration | 353257000 | JPY |
| Interest income noi | Prior1YearDuration | 3644000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 24 of 24 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |